These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9674803)

  • 1. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN
    Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
    Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Henry B; Brotchie JM
    Drugs Aging; 1996 Sep; 9(3):149-58. PubMed ID: 8877309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease.
    Van Blercom N; Lasa A; Verger K; Masramón X; Sastre VM; Linazasoro G
    Clin Neuropharmacol; 2004; 27(3):124-8. PubMed ID: 15190235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
    Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
    Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
    Elahi B; Phielipp N; Chen R
    Can J Neurol Sci; 2012 Jul; 39(4):465-72. PubMed ID: 22728853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate release inhibition ineffective in levodopa-induced motor complications.
    Bara-Jimenez W; Dimitrova TD; Sherzai A; Aksu M; Chase TN
    Mov Disord; 2006 Sep; 21(9):1380-3. PubMed ID: 16758479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.